AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05919875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Mindfulness-Based Cognitive Therapy
Description: The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises.
Study NCT06541990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HARMONY
Description: A psychoeducational intervention for patients with HCC
Study NCT06541990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: A supportive care resource guide
Study NCT06589557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality (VR) and Standard Rehabilitation
Description: VR Rehabilitation:~The VR therapy includes exercises designed to improve the range of motion, coordination, and spatial awareness of the cervical spine. Each patient will complete 15 training sessions over three weeks (5 sessions per week, 2 hours per session), with an additional 30 minutes of daily VR exercises.~Standard Rehabilitation Program:~Manual Therapy: Mobilization and manipulation techniques are applied to enhance the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises focus on improving body position awareness, movement, and balance.~Strengthening and Stretching Exercises: Individually tailored exercises are provided to strengthen and stretch the neck muscles.
Study NCT06589557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Rehabilitation
Description: Patients in this group will participate solely in the standard rehabilitation program.~Standard Rehabilitation Program:~Number of Sessions: Each patient will complete 15 training sessions, held 5 times per week for 3 weeks, with each session lasting 2 hours.~Program Components:~Manual Therapy: Mobilization and manipulation techniques will be applied to improve the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises aim to enhance body position awareness, movement control, and balance.~Strengthening and Stretching Exercises: Customized exercises will be provided to strengthen and stretch the neck muscles, tailored to individual needs.
Study NCT06526013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholesterol self-measurement
Description: Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
Study NCT06589700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
Study NCT06594172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily.
Study NCT06594172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily.
Study NCT06594172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)
Description: Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).
Study NCT06592170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib combination with obinutuzumab
Description: Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle.
Study NCT06604000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GMT Usual
Description: Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks.
Study NCT06604000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT Usual
Description: Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks.
Study NCT06604000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT Cuing
Description: The participants will receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP; as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends.
Study NCT06604000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT Boost
Description: After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response.
Study NCT06601985 — intervention group
Intervention type: PROCEDURE
Intervention: J-pouch anastomosis
Description: Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
Study NCT06601985 — intervention group
Intervention type: PROCEDURE
Intervention: direct anastomosis
Description: Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
Study NCT05257356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysical tasks
Description: Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
Study NCT05485896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Lenvatinib
Description: Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
Study NCT06603714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization
Description: We will perform instrument assisted soft tissue mobilization on calf muscles. The intervention will last 9 min. For the first minute of treatment light pressure will be applied for tissue preparation. Afterwards, four different strokes will be applied by maintaining the tool at a 30° of inclination for one minute. This will be repeated for a second set, with a tool inclination of 45°.
Study NCT06596200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation Implant
Description: Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord
Study NCT06589752 — intervention group
Intervention type: DRUG
Intervention: TARPEYO 4 MG Delayed Release Oral Capsule
Description: TARPEYO dispensing claim for any dose is exposure
Study NCT06589752 — intervention group
Intervention type: DRUG
Intervention: RAS inhibitor
Description: RASi dispensing claim for any dose is reference
Study NCT06382597 — intervention group
Intervention type: OTHER
Intervention: Nordic hamstring exercise
Description: Nordic Hamstring Exercise involves a controlled descent of the upright torso from a vertical kneeling position forward towards the ground (parallel to the ground) and returning to the starting position. The ankle joints are stabilized by the other person's grip during a series of exercises.
Study NCT06596057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T/CAR-NK cells
Description: One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion
Study NCT04887116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person.
Study NCT06705270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Response-focused education
Description: Once participants recover from sedation, they will receive education that is focused on their response to treatment.
Study NCT06705270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis-focused education
Description: Once participants recover from sedation, they will be provided education that is focused on their diagnosis of major depressive disorder.
Study NCT06706544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
Study NCT06706544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (placebo)
Description: Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study NCT06705322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cnidium Monnieri Detoxification Formula
Description: Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment.
Study NCT06513026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose-Containing Milk
Description: Participants will be asked to drink 1% regular milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit.
Study NCT06513026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose-Free Milk
Description: Participants will be asked to drink 1% lactose-free milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit.
Study NCT06412159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Selective laser melting framework was fabricated using completely digital workflow
Description: completely digital work flow Conventional technique versus complete digital technique
Study NCT05118022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system
Description: Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
Study NCT05587764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of Care
Description: Standard of care for emergency events per local guidelines.
Study NCT06192654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small intestinal submucosa (SIS) graft urethroplasty
Description: Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
Study NCT06192654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous oral bucal mucosa graft urethroplasty
Description: Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
Study NCT05727345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Preoperative ultrasound-guided interscalene brachial plexus block application
Study NCT05727345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder anterior capsular block
Description: Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
Study NCT06524297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse system (Patients)
Description: The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.
Study NCT06524297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse system (Resident Physician)
Description: The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
Study NCT05922878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-300
Description: ALTO-300 capsule QD
Study NCT05922878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule QD
Study NCT05731583 — intervention group
Intervention type: DEVICE
Intervention: Home pulse oximetry monitoring
Description: A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
Study NCT05256628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Weightbearing
Description: Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
Study NCT06078241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine infusion
Description: Intravenous lidocaine infusion
Study NCT06078241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Description: Unilateral erector spinae plane block
Study NCT06078241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of normal saline
Description: Intravenous infusion of normal saline
Study NCT06078241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ESPB with normal saline
Description: Unilateral ESPB with normal saline
Study NCT06550934 — intervention group
Intervention type: PROCEDURE
Intervention: Fracture stabilization
Description: isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
Study NCT06305182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
Study NCT06305182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
Study NCT05708196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).
Description: After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
Study NCT05708196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft bone grafting material.
Description: After tooth extraction, the tooth socket will be grafted with allograft grafting material
Study NCT05231954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
Study NCT05231954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.